Strong Hepatitis C Cocktail Contenders
Gilead’s Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study
— Compounds Among the Company’s Seven HCV Pipeline Candidates Spanning Six Therapeutic Classes —
BOSTON, Oct 30, 2010 (BUSINESS WIRE) — Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.
Continue reading this entire article: